The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1752
April 13, 2026
View Complete Issue         Table of Contents 2019 
Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
April 13, 2026 (Issue: 1752)
Plozasiran (Redemplo – Arrowhead), an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA), has been approved by the FDA to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). It is...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
Article code: 1752c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.